07:04pm Monday 25 September 2017

Surprising Discovery Could Help Scientists Refine Treatment for Advanced Melanoma

Malignant melanoma is the most deadly form of skin cancer and is difficult to treat successfully once it has spread to other organs. The BRAF gene is faulty in about half of malignant melanomas and many other cancers, making it a suitable drug target. Drugs that block BRAF function in cells are already showing positive results in early clinical trials in melanoma patients in the US. 

About half of the melanomas that do not have faults in BRAF have errors in a different protein called RAS. In this study, scientists examined the effect of drugs that block BRAF function on the melanomas with faulty RAS. They found that the drugs caused an unexpected activation of the processes that drive cancer cell growth. So one of the consequences of giving these drugs to patients with a faulty RAS gene is that the drug could encourage the melanoma to grow, rather than slow down.

Lead author Professor Richard Marais, a Cancer Research UK-funded scientist from The Institute of Cancer Research, said: “These unexpected findings give us much more insight into how BRAF drugs will behave in humans. These are preliminary laboratory findings, but they strongly suggest that BRAF drugs should not be given to patients who have faults in the RAS gene, because long-term use could accelerate tumour growth.

“This study highlights the importance of understanding the genetics of cancer to achieve therapeutic benefit. It will enable clinicians to select which patients they administer these drugs to, allowing them to personalise treatment for each patient. This research also provides the springboard for developing drugs that will work in patients whose tumours carry a faulty RAS gene.”

Dr Lesley Walker, director of cancer information at Cancer Research UK, said: “These findings provide an important insight into the genetic mechanisms of human cancer. They show how basic scientific research is vital to clinical care and emphasise the importance of understanding the makeup of individual cancers when using new targeted treatments of this type.

“The impact of this research will enable doctors’ testing BRAF inhibitors in the clinic to target the treatments more precisely to patients who will definitely benefit, and avoid treating those who won’t.”

– ENDS –

For more information, contact Emma Gilgunn-Jones in the Cancer Research UK press office on 0207 061 8311, or out-of-hours the duty press officer on 07050 264 059.

*Heidorn et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumour progression through CRAF. January 2010. Cell.

 

About malignant melanoma

  • Around 10,400 cases of malignant melanoma are diagnosed in the UK each year, and 2,000 people die from the disease. Malignant melanoma incidence rates in Britain have more than quadrupled since the 1970s.
  • There are two main types of skin cancer: non-melanoma skin cancer, which is very common, and malignant melanoma which is less common but more serious.
  • Registration of non-melanoma skin cancer is incomplete. Around 82,000 cases of non-melanoma skin cancer are registered but it is estimated that the actual number is at least 100,000 cases in the UK each year.
  • For more information about skin cancer and treatments, visit Cancer Research UK’s patient information website CancerHelp UK www.cancerhelp.org.uk
  • To search for BRAF inhibitor trials in the US, visit the clinical trials website for the US National Institutes of Health www.clinicaltrials.gov

 

About The Institute of Cancer Research (ICR)

  • The ICR is Europe’s leading cancer research centre.
  • The ICR has been ranked the UK’s top academic research centre, based on the results of the Higher Education Funding Council’s Research Assessment Exercise.
  • The ICR works closely with partner The Royal Marsden NHS Foundation Trust to ensure patients immediately benefit from new research. Together the two organisations form the largest comprehensive cancer centre in Europe.
  • The ICR has charitable status and relies on voluntary income, spending 95 pence in every pound of total income directly on research.
  • As a college of the University of London, the ICR also provides postgraduate higher education of international distinction.
  • Over its 100-year history, the ICR’s achievements include identifying the potential link between smoking and lung cancer which was subsequently confirmed, discovering that DNA damage is the basic cause of cancer and isolating more cancer-related genes than any other organisation in the world.
  • The ICR is home to the world’s leading academic drug development team. Several important anti-cancer drugs used worldwide were synthesised at the ICR and it has discovered an average of two preclinical candidates each year over the past five years.

For more information visit www.icr.ac.uk

 

About Cancer Research UK

  • Cancer Research UK is the world’s leading charity dedicated to beating cancer through research.
  • The charity’s groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.  This work is funded entirely by the public.
  • Cancer Research UK has been at the heart of the progress that has already seen survival rates double in the last thirty years.
  • Cancer Research UK supports research into all aspects of cancer through the work of more than 4,800 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK’s vision is to beat cancer.

For further information about Cancer Research UK’s work or to find out how to support the charity, please call 020 7121 6699 or visit www.cancerresearchuk.org


Share on:
or:

Health news